Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic value of PD-L1 with apatinib plus camrelizumab in advanced hepatocellular carcinoma
ChiCTR2100044694Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Overall survival and Progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100044694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044694.